Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Reported or proposed issue Pregnancy, breastfeeding, children, liver disease, or cancer history Evidence source No direct human safety data Known or theoretical
Call or message us at (786) 502-2260 to schedule a consultation with a licensed medical provider
The compound is referenced across a wide spectrum of preclinical models, with most literature focusing on three thematic areas: The 50mg and 100mg vial formats make GHK-Cu particularly suitable for extended research protocols where higher peptide volumes are required compared with the typical 510mg formats used for other research compounds
See our guide on combining peptides for more stacking guidance
This compound is not intended for therapeutic or diagnostic purposes and has not been evaluated by regulatory agencies for safety or efficacy in humans
In a phase 2 study, the medication showed up to 20% average weight loss at 52 weeks for people with obesity or overweight without diabetes and 17% for those with overweight/obesity and type 2 diabetes
US$ 20.41
US$ 27.01
US$ 22.14
